welcomes you to the new, improved website!An ad hoc interim analysis pursuant to previous publications raising concerns on Paclitaxel DCS in chronic critical and not-critical lower limb ischaemia. The short manuscript requires careful reading to form an individual opinion beyond the relatively simple arithmetics: slightly more deaths in the intervention group. The vasculopathic cohort had a 75% crude overall survival after only 2.5 years.
Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease
Submitted by: Aristotle Protopapas
Source: The New England Journal of Medicine
Keywords:
Author(s): Joakim Nordanstig, M.D., Ph.D., Stefan James, M.D., Ph.D., Manne Andersson, M.D., Ph.D., Mattias Andersson, M.D., Peter Danielsson, M.D., Ph.D., Peter Gillgren, M.D., Ph.D., Martin Delle, M.D., Ph.D., Jan Engström, M.D., Torbjörn Fransson, M.D., Maher Hamoud, M.D., Ph.D., Anna Hilbertson, M.D., Patrik Johansson, M.D., Lars Karlsson, M.D., Ph.D., Björn Kragsterman, M.D., Ph.D., Hans Lindgren, M.D., Ph.D., Karin Ludwigs, M.D., Stefan Mellander, M.D., Ph.D., Niklas Nyman, M.D., Henrik Renlund, Ph.D., Birgitta Sigvant, M.D., Ph.D., Per Skoog, M.D., Ph.D., Joachim Starck, M.D., Gustaf Tegler, M.D., Ph.D., Asko Toivola, M.D., Maria Truedson, M.D., Carl-Magnus Wahlgren, M.D., Ph.D., Jonas Wallinder, M.D., Andreas Öjersjö, M.D., and Mårten Falkenberg, M.D., Ph.D.